StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab) by Quarter

Direct Clinical R&D — Libtayo (cemiplimab) ($M) ($M)

Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab): $13.4M in Q3 2026, down 25.6% from a year earlier.

Latest, Q3 2026
13.4
Period ended Sep 30, 2026
Change on a year earlier
-25.6%
18 in Q3 2025
History
37 quarters
Since Q3 2017
Sources
34
Documents cited below

Where the Q3 2026 figure comes from

“R&D Expenses Table (FY2026Q3): Libtayo (cemiplimab) | 13.4 | 18.0 | (4.6) | 48.7 | 57.3 | (8.6)”

Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDirect Clinical R&D — Libtayo (cemiplimab) ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202613.4-25.6%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 202615.7-15.1%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 202619.7-5.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202518.8+2.2%Form 10-K (regn-20251231.htm; 0000872589-26-000034|regn-20260930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202518+0.6%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 202518.5-8.4%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 202520.8-8.0%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 202418.4-20.3%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 202417.9-25.1%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 202420.2-20.5%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 202422.6-31.3%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202323.1-25.2%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 202323.9-23.6%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202325.4-31.7%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 202332.9-14.8%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 202230.9-8.0%Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab) ($M), quarterly Q3 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-libtayo

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?